The use of taxanes in the neoadjuvant treatment of breast cancer: A review of randomized phase II/III trials

Clinical Breast Cancer

Volumn 7, Issue 10, 2007, Pages 764-774

  Tusquets, Ignasi ^a   Estévez, Laura G ^b   Alvarez, Isabel ^c   Muñoz, Montserrat ^d   Adrover, Encarna ^e   Albanell, Joan ^a   Rodríguez, César ^f   Seguí, Miguel Ángel ^g   Rodríguez Lescure, Alvaro ^h   Ruiz Borrego, Manuel ⁱ   García Mata, Jesús ^j   Lluch, Ana ^k  

^a HOSPITAL DEL MAR   (Spain)

^b FiHM Centro Integral Oncológico Hospital de Madrid Clara Campal   (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^f HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^g HOSPITAL DE SABADELL   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^j Servizo Galego de Saúde   (Spain)

^k HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

more..

Author keywords

Anthracyclines; Docetaxel; Induction chemotherapy; Paclitaxel; Trastuzumab

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; NAVELBINE; PACLITAXEL; PREDNISOLONE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINCRISTINE;

BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HORMONAL THERAPY; HUMAN; LEUKOPENIA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 36048976055     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2007.n.037     Document Type: Review

References (44)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717.
3. Bonadonna G, Valagussa P. The contribution of medicine to the primary treatment of breast cancer. Cancer Res 1988; 48:2314-2324.
4. Bonadonna G, Valagussa P. Primary chemotherapy in operable breast cancer. Semin Oncol 1996; 23:464-474.
5. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16:2672-2685.
6. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97:188-194.
7. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001; 2001:96-102.
8. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999; 17:460-469.
9. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or post-operative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Froject Protocol B-27. J Clin Oncol 2006; 24:2019-2027.
10. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21:968-975.
11. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19:1707-1715.
12. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302-2313.
13. Martín M, Rodríguez-Lescure A, Ruiz A, et al. Multicenter, randomized phase III study of adjuvant chemotherapy for node-positive breast cancer comparing 6 cycles of FE90C versus 4 cycles of FE90C followed by 8 weekly paclitaxel administrations: interim efficacy analysis of GEICAM 9906 trial. Presented at: 2005 San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, TX.
14. Roche H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006; 24:5664-5671.
15. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23:3686-3696.
16. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003; 21:976-983.
17. Gogas H, Fountzilas G. The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer. Ann Oncol 2003; 14:667-674.
18. Estevez LG, Gradishar WJ. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res 2004; 10:3249-3261.
19. Evans TR, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 2005; 23:2988-2995.
20. Dieras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22:4958-4965.
21. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21:4165-4174.
22. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20:1456-1466.
23. Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005; 11(24 Pt 1):8715-8721.
24. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 2005; 23:2676-2685.
25. Green MC, Buzdar AU, Smith T, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 2005; 23:5983-5992.
26. von Minckwitz G, Blohmer J, Vogel P, et al. Comparison of neoadjuvant 6 vs 8 cycles of docetaxel/doxorubicin/cyclophosphamide (TAC) in patients early responding to TACx2-the GEPARTRIO Study. J Clin Oncol 2006; 24(18 suppl):21s (Abstract #576).
27. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23:3676-3685.
28. Gianni L, Baselga J, Eiermann W, et al. European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol 2005; 23(16 suppl):7s (Abstract #513).
29. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007; 13:228-233.
30. Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16:223-228.
31. Goldstein L, O'Neill A, Sparano J, et al. E2197: phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol 2005; 23(16 suppl):7s (Abstract #512).
32. Hutcheon AW, Heys SD, Sarkar TK. Docetaxel primary chemotherapy in breast cancer: a five year update on the Aberdeen trial. Breast Cancer Res Treat 2003; 82(suppl 1):S6 (Abstract #11).
33. Albain K, Green S, Ravdin P, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 2002; 21:37a (Abstract #143).
34. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983; 43:1488-1492.
35. Chollet P, Amat S, Cure H, et al. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86:1041-1046.
36. von Minckwitz G, Costa SD, Raab G, et al. Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study. J Clin Oncol 2001; 19:3506-3515.
37. von Minckwitz G, Costa SD, Eiermann W, et al. Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol 1999; 17:1999-2005.
38. Seidman AD, Norton L. Comparison of paclitaxel regimens. Curr Oncol Rep 2005; 7:7-8.
39. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 1999; 26(4 suppl 12):78-83.
40. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684.
41. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369:29-36.
42. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23:4265-4274.
43. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-792.
44. von Minckwitz G, Blohmer JU, Raab G, et al. In vivo chemosensitivity- adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol 2005; 16:56-63.